Literature DB >> 27783906

Child-Parent Familial Hypercholesterolemia Screening in Primary Care.

David S Wald1, Jonathan P Bestwick1, Joan K Morris1, Ken Whyte1, Lucy Jenkins1, Nicholas J Wald1.   

Abstract

BACKGROUND: Child-parent screening for familial hypercholesterolemia has been proposed to identify persons at high risk for inherited premature cardiovascular disease. We assessed the efficacy and feasibility of such screening in primary care practice.
METHODS: We obtained capillary blood samples to measure cholesterol levels and to test for familial hypercholesterolemia mutations in 10,095 children 1 to 2 years of age during routine immunization visits. Children were considered to have positive screening results for familial hypercholesterolemia if their cholesterol level was elevated and they had either a familial hypercholesterolemia mutation or a repeat elevated cholesterol level 3 months later. A parent of each child with a positive screening result for familial hypercholesterolemia was considered to have a positive screening result for familial hypercholesterolemia if he or she had the same mutation as the child or, if no mutations were identified, had the higher cholesterol level of the two parents.
RESULTS: The use of a prespecified cholesterol cutoff value of 1.53 multiples of the median (MoM, corresponding to a percentile of 99.2) identified 28 children who had positive screening results for familial hypercholesterolemia (0.3% of the 10,095 children; 95% confidence interval [CI], 0.2 to 0.4), including 20 with a familial hypercholesterolemia mutation and 8 with a repeat cholesterol level of at least 1.53 MoM. A total of 17 children who had a cholesterol level of less than 1.53 MoM also had a familial hypercholesterolemia mutation. The overall mutation prevalence was 1 in 273 children (37 in 10,095; 95% CI, 1 in 198 to 1 in 388). The use of an initial cholesterol cutoff value of 1.35 MoM (95th percentile) plus a mutation, or two cholesterol values of at least 1.50 MoM (99th percentile), identified 40 children who had positive screening results for familial hypercholesterolemia (0.4% of the 10,095 children, including 32 children who had a familial hypercholesterolemia mutation and 8 who did not have the mutation) and 40 parents who had positive screening results for familial hypercholesterolemia.
CONCLUSIONS: Child-parent screening was feasible in primary care practices at routine child immunization visits. For every 1000 children screened, 8 persons (4 children and 4 parents) were identified as having positive screening results for familial hypercholesterolemia and were consequently at high risk for cardiovascular disease. (Funded by the Medical Research Council.).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27783906     DOI: 10.1056/NEJMoa1602777

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  59 in total

1.  Dyslipidaemia: Optimizing child-parent screening for FH.

Authors:  Dario Ummarino
Journal:  Nat Rev Cardiol       Date:  2016-11-17       Impact factor: 32.419

2.  Identifying Familial Hypercholesterolemia Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors.

Authors:  Candace L Jackson; James Z Keeton; Stephen J Eason; Zahid A Ahmad; Colby R Ayers; M Odette Gore; Darren K McGuire; Merlyn H Sayers; Amit Khera
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

3.  Reverse cascade screening for familial hypercholesterolemia in high-risk Chinese families.

Authors:  Xue Wu; Jing Pang; Xumin Wang; Jie Peng; Yan Chen; Shilong Wang; Gerald F Watts; Jie Lin
Journal:  Clin Cardiol       Date:  2017-11-23       Impact factor: 2.882

4.  LDL cholesterol level in fifth-grade schoolchildren associates with stature.

Authors:  Lee A Pyles; Christa L Lilly; Charles J Mullett; Emily S Polak; Eloise M Elliott; William A Neal
Journal:  J Lipid Res       Date:  2017-09-04       Impact factor: 5.922

5.  Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals.

Authors:  Yumi Yamaguchi-Kabata; Jun Yasuda; Osamu Tanabe; Yoichi Suzuki; Hiroshi Kawame; Nobuo Fuse; Masao Nagasaki; Yosuke Kawai; Kaname Kojima; Fumiki Katsuoka; Sakae Saito; Inaho Danjoh; Ikuko N Motoike; Riu Yamashita; Seizo Koshiba; Daisuke Saigusa; Gen Tamiya; Shigeo Kure; Nobuo Yaegashi; Yoshio Kawaguchi; Fuji Nagami; Shinichi Kuriyama; Junichi Sugawara; Naoko Minegishi; Atsushi Hozawa; Soichi Ogishima; Hideyasu Kiyomoto; Takako Takai-Igarashi; Kengo Kinoshita; Masayuki Yamamoto
Journal:  J Hum Genet       Date:  2017-12-01       Impact factor: 3.172

6.  Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk.

Authors:  Florent Séguro; Jean-Pierre Rabès; Dorota Taraszkiewicz; Jean-Bernard Ruidavets; Vanina Bongard; Jean Ferrières
Journal:  Clin Cardiol       Date:  2018-03-25       Impact factor: 2.882

7.  Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing.

Authors:  Joshua W Knowles; Daniel J Rader; Muin J Khoury
Journal:  JAMA       Date:  2017-07-25       Impact factor: 56.272

Review 8.  Statins for children with familial hypercholesterolemia.

Authors:  Alpo Vuorio; Jaana Kuoppala; Petri T Kovanen; Steve E Humphries; Serena Tonstad; Albert Wiegman; Euridiki Drogari; Uma Ramaswami
Journal:  Cochrane Database Syst Rev       Date:  2017-07-07

Review 9.  Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.

Authors:  Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray
Journal:  Nat Rev Cardiol       Date:  2020-01-23       Impact factor: 32.419

Review 10.  Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care.

Authors:  Sujana Balla; Eson P Ekpo; Katherine A Wilemon; Joshua W Knowles; Fatima Rodriguez
Journal:  Curr Atheroscler Rep       Date:  2020-08-20       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.